Delving into the Latest Updates on Cisplatin/Epinephrine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CDDP TI, IntraDose-CDDP, MPI-5010

Target

ADRA1 x DNA x β-adrenoceptors

Mechanism

ADRA1 agonists(Adrenergic receptor alpha-1 agonists), DNA inhibitors(DNA inhibitors), β-adrenoceptors agonists(Beta adrenergic receptors agonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [1]

Active Indication-

Inactive Indication

Breast CancerEsophageal CarcinomaHead and Neck Neoplasms+ [6]

Originator Organization

Novartis Pharma AG

Active Organization-

Inactive Organization

Novartis Pharma AG

Novartis AGMatrix Pharmaceutical, Inc.

Drug Highest PhasePendingPhase 3

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaCl2H6N2Pt

InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N

CAS Registry15663-27-1

View All Structures (2)

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cisplatin-epinephrine injectable gel plus paclitaxel and carboplatin in treating patients who have recurrent head and neck cancer.

Start Date01 Nov 2000

Sponsor / Collaborator

Matrix Pharmaceutical, Inc.

NCT00003044 / Unknown statusPhase 2

A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cisplatin and epinephrine administered directly into the tumor in treating patients who have primary liver cancer that cannot be removed during surgery.

Start Date01 Sep 1996

Sponsor / Collaborator

Matrix Pharmaceutical, Inc.

NCT00002659 / Unknown statusPhase 3

A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer.
PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer.

Start Date01 May 1995

Sponsor / Collaborator

Matrix Pharmaceutical, Inc.

100 Clinical Results associated with Cisplatin/Epinephrine

Login to view more data

100 Translational Medicine associated with Cisplatin/Epinephrine

Login to view more data

100 Patents (Medical) associated with Cisplatin/Epinephrine

Login to view more data

240

Literatures (Medical) associated with Cisplatin/Epinephrine

01 Feb 2024·Angiology

The Role of Anticoagulants and Platelet Aggregation Inhibitors in the Treatment of Pseudoaneurysms and Risk of Venous Thrombosis

Article

Author: Juenger, Jonas ; Udelnow, Andrei ; Braun-Dullaeus, Ruediger C. ; Bauersachs, Rupert ; Herold, Joerg ; Mahlmann, Adrian

Pseudoaneurysms (PSA) are one of the most common complications after arterial punctures. This retrospective study examined whether platelet aggregation inhibitors (APT) or anticoagulants (AC) lower the success rates of PSA treatment. A total of 468 patients with PSA were retrospectively analyzed between 2010 and 2018, and 238 were included in the study. Despite co-medication with APT or AC, thrombin injection (TI) was superior to compression bandage (CB) therapy in treating PSA (TIwAC 79 vs CBwAC 51%; P = .004 and TIwAPT 93 vs CBwAPT 54%; P = .001). There was no decrease in PSA-associated thrombosis in patients requiring anticoagulation after TI. The success rates of the TI and CB groups were compared in patients with and without AC therapy, and the latter was significantly lower. A reduced success rate was not observed in CB therapy patients requiring APT. In contrast, better results were seen in the TI group. Regarding PSA treatment, TI therapy is significantly superior to CB, including in patients requiring concomitant AC or APT therapy. PSA-associated thrombosis also occurs in patients requiring anticoagulation, and sonography should be performed. Concomitant medication use with APT does not significantly influence PSA therapy success or prevention of PSA-associated thrombosis.

01 Jan 2024·International immunopharmacology

Tanshinone I attenuates estrogen-deficiency bone loss via inhibiting RANKL-induced MAPK and NF-κB signaling pathways

Article

Author: Wang, Xiaochao ; Ma, Chao ; Wang, Zhangzheng ; Niu, Wei ; Zhou, Guangquan ; Liu, Yuhao ; Yi, Chunzhi ; Mo, Liang

AIM OF THE STUDY:

This study aims to reveal the role of Tanshinone I (TI) in inhibiting osteoclast activity and bone loss in vitro and in vivo, as well as elucidate its underlying molecular mechanism.

MATERIALS AND METHODS:

A mouse model of estrogen deficiency was used to assess the inhibitory effect of TI on osteoclast activity and subsequent bone loss. To validate the impact of TI on osteoclast formation, TRAcP staining and pseudopodia belt staining were conducted. The expressions of osteoclast-specific genes and proteins were evaluated using RT-PCR and Western Blot analyses. Additionally, immunofluorescence staining was employed to examine the effect of TI on p65 nuclear translocation and the expression level of reactive oxygen species (ROS).

RESULTS:

TI demonstrated significant efficacy in alleviating bone mass loss and suppressing osteoclast activity and function in ovariectomized mice. This outcome was predominantly ascribed to a decrease in ROS levels, thereby impeding the NF-κB signaling pathway and the translocation of p65 to the nucleus. Additionally, TI hindered the RANKL-induced phosphorylation of the MAPK signaling pathway. Moreover, TI played a role in the reduction of osteoclast-specific genes and proteins.

CONCLUSIONS:

To summarize, this study sheds light on TI's capacity to modulate various signaling pathways triggered by RANKL, effectively impeding osteoclast formation and mitigating bone loss resulting from estrogen deficiency. Consequently, TI emerges as a promising therapeutic option for estrogen-deficiency bone loss.

17 Dec 2023·Natural product research

The interaction of anti-inflammatory and anti-tumor components in the traditional Chinese medicine Solanum lyratum Thunb

Article

Author: Hu, Xuebo ; Faruque, Mohammad Omar ; Luo, Biaobiao ; Chen, Jian ; Hu, Sheng ; Zhou, Xinxin ; Li, Xiaohua ; Zou, Dian

Solanum lyratum Thunb is a traditional Chinese medicinal with a significant clinical outcome for tumor treatment; however, chemicals or fractions separated from the herb did not exhibit strong and comparable efficacy. To investigate the potential synergy or antagonism among chemicals in the extract, we obtained the compounds solavetivone (SO), tigogenin (TI) and friedelin (FR) from the herb. The anti-tumor effects of these three monomer compounds alone or in combination with the anti-inflammatory compound DRG were also tested in this study. SO, FR and TI used alone did not inhibit the proliferation of A549 and HepG2 cells, but the combination of the three achieved 40% inhibition. In vitro anti-inflammatory analysis showed that DRG had a stronger anti-inflammatory effect than TS at the same concentration, and the combination of DRG with SO, FR or TI inhibited the anti-tumor effect of DRG. This is the first study that documented the synergistic and antagonistic interactions between different compounds in a single herb.

100 Deals associated with Cisplatin/Epinephrine

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	CA	Matrix Pharmaceutical, Inc.	01 May 1995
Breast Cancer	Phase 3	US	Novartis AG	-
Breast Cancer	Phase 3	-	Novartis AG	-
Breast Cancer	Phase 3	-	Novartis Pharma AG	-
Esophageal Carcinoma	Phase 3	US	Novartis AG	-
Esophageal Carcinoma	Phase 3	EU	-	-
Esophageal Carcinoma	Phase 3	-	Novartis Pharma AG	-
Liver Cancer	Phase 3	-	Novartis Pharma AG	-
Lung Cancer	Phase 3	US	Novartis AG	-
Lung Cancer	Phase 3	-	Novartis AG	-